Literature DB >> 18277118

Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.

Pedro Iglesias1, Guillermo Ais, Ana González, Pilar Tajada, Carmen García Arévalo, Enrique Fernández Pardo, Juan J Díez.   

Abstract

OBJECTIVE: We report the acute effects of cinacalcet on calcium and parathyroid hormone (PTH) levels and the effects of 1 year of therapy on calcium and phosphorus metabolism in 4 patients with persistent primary hyperparathyroidism (PHPT) after unsuccessful parathyroidectomy. PATIENTS: Four patients (3 women; age, 24 to 71 years) were studied after 1 to 3 parathyroid operative procedures. All of them had elevated serum total and ionized calcium levels, decreased serum phosphorus, and increased concentrations of intact PTH.
METHODS: Calcium and PTH responses to an acute dose of oral cinacalcet (30 mg) were studied at baseline. Effects of cinacalcet (30 mg b.i.d.) on serum calcium, phosphorus, and PTH, and urinary calcium and phosphorus were studied at 1, 3, 6, and 12 months of therapy.
RESULTS: PTH concentrations were reduced by 13.0% to 86.7% after acute cinacalcet administration. Chronic therapy with cinacalcet was followed by a decrement in serum total calcium (10.2% at 12 months) and ionized calcium (10.1%) and an increase in serum phosphorus (20.8%), with only a modest decrement in PTH levels (5.1%). All patients had normal serum total and ionized calcium levels at 3 to 12 months of therapy. Urinary calcium decreased by 20.0% at 12 months.
CONCLUSIONS: Cinacalcet was effective in normalizing calcium and phosphorus concentrations in patients with persistent PHPT after unsuccessful parathyroidectomy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18277118     DOI: 10.1097/MAJ.0b013e3181379f3e

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  6 in total

Review 1.  Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.

Authors:  Leonidas H Duntas; Nikolaos Stathatos
Journal:  Endocrine       Date:  2011-03-26       Impact factor: 3.633

Review 2.  Primary hyperparathyroidism.

Authors:  John P Bilezikian; Natalie E Cusano; Aliya A Khan; Jian-Min Liu; Claudio Marcocci; Francisco Bandeira
Journal:  Nat Rev Dis Primers       Date:  2016-05-19       Impact factor: 52.329

3.  Cinacalcet treatment of primary hyperparathyroidism.

Authors:  H M Rothe; O Liangos; P Biggar; A Petermann; M Ketteler
Journal:  Int J Endocrinol       Date:  2011-03-06       Impact factor: 3.257

Review 4.  Bone turnover markers in primary hyperparathyroidism.

Authors:  Aline G Costa; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

Review 5.  Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus.

Authors:  A A Khan; D A Hanley; R Rizzoli; J Bollerslev; J E M Young; L Rejnmark; R Thakker; P D'Amour; T Paul; S Van Uum; M Zakaria Shrayyef; D Goltzman; S Kaiser; N E Cusano; R Bouillon; L Mosekilde; A W Kung; S D Rao; S K Bhadada; B L Clarke; J Liu; Q Duh; E Michael Lewiecki; F Bandeira; R Eastell; C Marcocci; S J Silverberg; R Udelsman; K Shawn Davison; J T Potts; M L Brandi; J P Bilezikian
Journal:  Osteoporos Int       Date:  2016-09-09       Impact factor: 4.507

Review 6.  Calcimimetics in CKD-results from recent clinical studies.

Authors:  Georg Schlieper; Jürgen Floege
Journal:  Pediatr Nephrol       Date:  2008-07-02       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.